Becton Dickinson Price to Free Cash Flow Ratio 2012-2025 | BDX
Historical price to free cash flow ratio values for Becton Dickinson (BDX) since 2012.
| Becton Dickinson Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-03-05 | 169.94 | 23.51 | |
| 2025-12-31 | 152.57 | $7.23 | 21.10 |
| 2025-09-30 | 146.35 | $9.25 | 15.81 |
| 2025-06-30 | 133.96 | $8.82 | 15.19 |
| 2025-03-31 | 177.07 | $9.03 | 19.61 |
| 2024-12-31 | 174.58 | $10.21 | 17.10 |
| 2024-09-30 | 184.65 | $10.72 | 17.23 |
| 2024-06-30 | 178.26 | $11.28 | 15.81 |
| 2024-03-31 | 188.00 | $10.51 | 17.89 |
| 2023-12-31 | 184.50 | $9.20 | 20.05 |
| 2023-09-30 | 194.83 | $7.34 | 26.55 |
| 2023-06-30 | 198.28 | $6.06 | 32.73 |
| 2023-03-31 | 185.24 | $4.45 | 41.62 |
| 2022-12-31 | 189.56 | $4.67 | 40.57 |
| 2022-09-30 | 165.49 | $5.21 | 31.75 |
| 2022-06-30 | 182.48 | $4.25 | 42.94 |
| 2022-03-31 | 191.44 | $3.91 | 48.92 |
| 2021-12-31 | 180.39 | $6.86 | 26.31 |
| 2021-09-30 | 175.71 | $10.04 | 17.50 |
| 2021-06-30 | 173.27 | $11.27 | 15.38 |
| 2021-03-31 | 172.64 | $12.33 | 14.00 |
| 2020-12-31 | 177.06 | $10.10 | 17.52 |
| 2020-09-30 | 164.08 | $7.68 | 21.37 |
| 2020-06-30 | 168.16 | $8.80 | 19.10 |
| 2020-03-31 | 160.96 | $9.08 | 17.72 |
| 2019-12-31 | 189.89 | $10.32 | 18.41 |
| 2019-09-30 | 176.08 | $8.64 | 20.39 |
| 2019-06-30 | 174.90 | $8.86 | 19.75 |
| 2019-03-31 | 172.76 | $7.57 | 22.83 |
| 2018-12-31 | 155.39 | $7.11 | 21.85 |
| 2018-09-30 | 179.42 | $7.44 | 24.10 |
| 2018-06-30 | 164.20 | $7.36 | 22.30 |
| 2018-03-31 | 148.05 | $6.97 | 21.24 |
| 2017-12-31 | 145.75 | $7.84 | 18.59 |
| 2017-09-30 | 132.96 | $8.15 | 16.31 |
| 2017-06-30 | 131.90 | $6.25 | 21.12 |
| 2017-03-31 | 123.54 | $8.58 | 14.39 |
| 2016-12-31 | 111.05 | $7.99 | 13.90 |
| 2016-09-30 | 120.03 | $8.58 | 13.99 |
| 2016-06-30 | 112.84 | $9.16 | 12.32 |
| 2016-03-31 | 100.62 | $7.76 | 12.97 |
| 2015-12-31 | 101.67 | $6.11 | 16.63 |
| 2015-09-30 | 87.16 | $5.46 | 15.95 |
| 2015-06-30 | 92.65 | $4.30 | 21.53 |
| 2015-03-31 | 93.52 | $4.11 | 22.78 |
| 2014-12-31 | 90.27 | $5.21 | 17.34 |
| 2014-09-30 | 73.51 | $5.53 | 13.30 |
| 2014-06-30 | 76.05 | $6.84 | 11.12 |
| 2014-03-31 | 74.92 | $6.73 | 11.13 |
| 2013-12-31 | 70.37 | $6.21 | 11.34 |
| 2013-09-30 | 63.38 | $5.67 | 11.18 |
| 2013-06-30 | 62.31 | $4.72 | 13.21 |
| 2013-03-31 | 59.98 | $5.45 | 11.01 |
| 2012-12-31 | 48.78 | $5.27 | 9.26 |
| 2012-09-30 | 48.70 | $5.45 | 8.94 |
| 2012-06-30 | 46.06 | $5.03 | 9.16 |
| 2012-03-31 | 47.55 | $4.05 | 11.73 |
| 2011-12-31 | 45.49 | $3.83 | 11.87 |
| 2011-09-30 | 44.36 | $4.59 | 9.66 |
| 2011-06-30 | 51.87 | $4.35 | 11.94 |
| 2011-03-31 | 47.69 | $4.59 | 10.38 |
| 2010-12-31 | 50.37 | $4.63 | 10.87 |
| 2010-09-30 | 43.93 | $4.00 | 10.98 |
| 2010-06-30 | 39.88 | $4.39 | 9.09 |
| 2010-03-31 | 46.19 | $4.43 | 10.43 |
| 2009-12-31 | 46.05 | $4.29 | 10.74 |
| 2009-09-30 | 40.53 | $3.90 | 10.38 |
| 2009-06-30 | 41.24 | $3.34 | 12.35 |
| 2009-03-31 | 38.69 | $3.29 | 11.76 |
| 2008-12-31 | 39.15 | $3.06 | 12.80 |
| 2008-09-30 | 45.71 | $3.85 | 11.87 |
| 2008-06-30 | 46.15 | $3.62 | 12.74 |
| 2008-03-31 | 48.56 | $3.08 | 15.76 |
| 2007-12-31 | 47.13 | $3.30 | 14.27 |
| 2007-09-30 | 46.11 | $2.56 | 18.04 |
| 2007-06-30 | 41.73 | $2.78 | 15.03 |
| 2007-03-31 | 42.93 | $2.61 | 16.44 |
| 2006-12-31 | 39.04 | $3.06 | 12.75 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $50.083B | $21.840B |
| Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $114.495B | 24.87 |
| Cardinal Health (CAH) | United States | $51.955B | 22.98 |
| West Pharmaceutical Services (WST) | United States | $18.021B | 34.36 |
| Cooper (COO) | United States | $16.264B | 20.09 |
| Align Technology (ALGN) | United States | $13.401B | 22.75 |
| Henry Schein (HSIC) | United States | $9.205B | 16.22 |
| Merit Medical Systems (MMSI) | United States | $4.842B | 23.81 |
| DENTSPLY SIRONA (XRAY) | United States | $2.583B | 8.20 |
| CONMED (CNMD) | United States | $1.294B | 9.07 |
| STAAR Surgical (STAA) | United States | $0.801B | 0.00 |
| Pro-Dex (PDEX) | United States | $0.127B | 15.07 |
| Lifevantage (LFVN) | United States | $0.064B | 6.62 |
| Axe Compute (AGPU) | United States | $0.008B | 0.00 |